Community Health Awareness of Diabetes (CHAD): Description of a Community-Wide Diabetes Awareness Demonstration Program and its Feasibility

Canadian Journal of Diabetes

Volumn 37, Issue 5, 2013, Pages 294-300

  Agarwal, Gina ^a   Kaczorowski, Janusz ^b   Hanna, Steven ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Community; Diabetes; Primary care; Risk assessment; Screening

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; AWARENESS; BLOOD ANALYSIS; CANADA; CAPILLARY BLOOD; COMMUNITY CARE; DIABETES MELLITUS; FAST FOOD; FAT INTAKE; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH EDUCATION; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SALT INTAKE; SELF EVALUATION; SYSTOLIC BLOOD PRESSURE; AGED; ATTITUDE TO HEALTH; BLOOD; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; HEALTH PROMOTION; HYPERTENSION; MASS SCREENING; METABOLISM; MIDDLE AGED; PILOT STUDY; PROGRAM EVALUATION; REPRODUCIBILITY; RISK REDUCTION;

AGED; AWARENESS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COMMUNITY NETWORKS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEASIBILITY STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; MALE; MASS SCREENING; MIDDLE AGED; ONTARIO; PILOT PROJECTS; PROGRAM EVALUATION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84884680199     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.07.001     Document Type: Article

References (33)

1. Lipscombe L., Hux J. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007, 369:750-756.
2. Hogan P., Dall T., Nikolov P. American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003, 26:917-932.
3. Harris R., Donahue K., Rathore S.S., et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003, 138:215-229.
4. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle and metformin. NEngl J Med 2002, 346:393-403.
5. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003, 27:s2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee.
6. Screening for type 2 diabetes. Diabetes Care 2003, 26(suppl 1):S21-S24. American Diabetes Association.
7. Chen T.H., Yen M.F., Tung T.H. Acomputer simulation model for cost-effectiveness analysis of mass screening for type 2 diabetes mellitus. Diabetes Res Clin Pract 2001, 54(suppl 1):S37-S42.
8. Kuo H.S., Chang H.J., Chou P., et al. AMarkov chain model to assess the efficacy ofscreening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 1999, 28:233-240.
9. Edelman D., Olsen M.K., Dudley T.K., et al. Utility of hemoglobin A1c in predicting diabetes risk. JGen Intern Med 2004, 19:1175-1180.
10. Ealovega M.W., Tabaei B.P., Brandle M., et al. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care 2004, 27:9-12.
11. Tabaei B.P., Burke R., Constance A., et al. Community based screening for diabetes in Michigan. Diabetes Care 2003, 26:668-670.
12. Lawrence J.M., Bennet P., Young A., et al. Screening for diabetes in general practice: cross sectional population study. BMJ 2001, 323:548-551.
13. Tsuyuki R.T., Johnson J.A., Teo K.K., et al. Arandomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002, 162:1149-1155.
14. Grant T., Soriano Y., Marantz P.R., et al. Community based screening for cardiovascular disease and diabetes using HbA1c. Am J Prev Med 2004, 26:271-275.
15. Feig D.S., Palda V.A., Lipscombe L., et al. Screening for type 2 diabetes mellitus to prevent vascular complications. CMAJ 2005, 172:177-180.
16. Lindstrom J., Tuomilehto J. The diabetes risk score, a practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26:725-731.
17. Park P., Griffin S., Sargeant L., et al. The performance of a risk score in predicting undiagnosed hyperglycaemia. Diabetes Care 2002, 25:984-988.
18. Peters A.L., Davidson M.B., Schriger D.L., et al. Aclinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-Analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 1996, 276:1246-1252.
19. Rolka D.B., Narayan K.M., Thompson T.J., et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2001, 24:1899-1903.
20. Fereday J., Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods 2006, 5:1-11.
21. SPSSversion 14.
22. Statistics Canada. 2001 community profiles. Released June 27, 2002. Last modified: 2005-11-30. Statistics Canada catalogue no. 93F0053XIE. 2002.
23. Janssen P.G., Gorter K.J., Stolk R.P., et al. Low yield of population-based screening for type 2 diabetes in The Netherlands: the ADDITION Netherlands study. Fam Pract 2007, 24:555-561.
24. Berglund G., Nilsson P., Eriksson K.-F., et al. Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity. JIntern Med 2000, 247:19-29.
25. Tsuyuki R.T., Johnson J.A., Teo K.K., et al. Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacother 1999, 33:910-919.
26. Waugh N., Scotland G., McNamee P., et al. Screening for type 2 diabetes: literature review and economic modelling exercise. Health Technol Assess 2007, 11:1-125. iii-iv, ix-xi.
27. Glumer C., Jorgensen T., Borch-Johnsen K. Targeted screening for undiagnosed diabetes reduces the number of diagnostic tests. Diabet Med 2004, 21:874-880.
28. Kaczorowski J., Karwalajtys T., Chambers L., et al. Community strategies to monitor high blood pressure among older adults (abstr) February 1, 2002, Pharmacy Practice Research Symposium, Toronto, Ontario.
29. Posavac E., Kattapong K. Peer -based interventions to influence health-related behaviors and attitudes: a meta-analysis. Psychol Rep 1999, 85:1179-1194.
30. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus 1999, World Health Organization, World Health Organization, Geneva.
31. Ekoe J., Punthakee Z., Ransom T., et al. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: screening for type 1 and type 2 diabetes. Can J Diabetes 2013, 37(suppl 1):S12-S15.
32. Robinson C.A., Agarwal G., Nerenberg K. Validating the CANRISK prognostic model for assessing diabetes risk in Canada's multi-ethnic population. Chronic Dis Inj Can 2011, 32:19-31.
33. Goldenberg R.M., Cheng A.Y.Y., Punthakee Z., et al. Position statement: use of glycated hemoglobin (A1C) in the diagnosis of type 2 diabetes mellitus in adults. Can J Diabetes 2011, 35:247-249.